|
Dr. Saxton 64 has been a director of the Company since December 2006. Dr. Saxton brings over 41 years of experience in pharmaceutical drug development to inVentiv initially as a clinical investigator and later through more than 25 years with Pfizer Inc. until his retirement in 2001. During his time with Pfizer Dr. Saxton worked in a variety of positions in both Europe and the USA in the R&D and International commercial divisions.
Throughout the 1990’s he was responsible for Pfizer’s worldwide pre-clinical and clinical development operations a period in which Pfizer enjoyed it’s most successful growth powered by an unprecedented number of worldwide approvals and launches of new chemical entity pharmaceutical products.
Each of these numerous approved products subsequently achieved peak sales in excess of $750 million dollars totaling more than $25 billion in annual revenue in recent years.
Dr. Saxton is also Chairman of the Board of Neurogen Inc. and a director of Conjuchem Inc. | 